Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Retained Earnings (2022 - 2025)

Taysha Gene Therapies' Retained Earnings history spans 4 years, with the latest figure at -$1.1 million for Q3 2025.

  • For Q3 2025, Retained Earnings rose 99.8% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$1.1 million, up 99.8%, while the annual FY2024 figure was -$4.0 million, 99.21% up from the prior year.
  • Retained Earnings for Q3 2025 was -$1.1 million at Taysha Gene Therapies, up from -$650.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1.1 million in Q3 2025 and bottomed at -$650.7 million in Q2 2025.
  • The 4-year median for Retained Earnings is -$443.7 million (2023), against an average of -$416.5 million.
  • The largest annual shift saw Retained Earnings crashed 62.08% in 2023 before it soared 99.8% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$401.4 million in 2022, then dropped by 27.79% to -$513.0 million in 2023, then soared by 99.21% to -$4.0 million in 2024, then skyrocketed by 71.64% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Retained Earnings are -$1.1 million (Q3 2025), -$650.7 million (Q2 2025), and -$623.8 million (Q1 2025).